The Efficacy of Hyperthermic Intraperitoneal Chemotherapy to Ovarian Cancer Patients With Homologous Recombination Repair Defect and Residual: a Prospective Cohort Study
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Age
18–70
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Age 18-70 years
Eastern Cooperative Oncology Group (ECOG) score 0-1
Adequate kidney function (blood creatinine 58-96µmol/L)
Adequate haematological function (haemoglobin ≥110g/L, leucocytes ≥4.0×109/L, neutrophils ≥2.0×109/L, platelets≥100×109/L)
Adequate liver function (serum total bilirubin 3.4-22.2µmol/L, alanine aminotransferase (ALT) 7-40U/L, aspartate aminotransferase (AST) 13-35U/L, AST/ALT ≤1.5
surgery with residual
eligible to the maintenance therapy of olaparib plus bevacizumab
You may not be if
Expected life span ≤8 weeks
Complicated with any other known malignancies
Patients with dysfunction of swallow and digestion
Patients who had received any kind of poly adenosinediphosphate-ribose polymerase（PARP）inhibitor
refractory hypertension
Clareo Health | The Efficacy of Hyperthermic Intraperitoneal Chemotherapy to Ovarian Cancer Patients With Homologous Recombination Repair Defect and Residual: a Prospective Cohort Study
